GILD · News · 20260816N

Product / Drug Pipeline Progress

GILEAD SCIENCES, INC. · 2026-08-16 · Importance 31 · Surprise 42

Gilead’s partnered GS-1179 program with Assembly Biosciences is advancing into Phase 2 development for genital herpes. Assembly’s ABI-6250 is also progressing in chronic hepatitis D virus, primary biliary cholangitis, and primary sclerosing cholangitis. Multiple clinical readouts are expected in 2027–2028, with Gilead’s economics structured around milestone and royalty payments or a 40% cost-profit share.